Prednisone, Lupus Activity, and Permanent Organ Damage

被引:182
作者
Thamer, Mae [1 ]
Hernan, Miguel A. [2 ,3 ]
Zhang, Yi [1 ]
Cotter, Dennis [1 ]
Petri, Michelle [4 ]
机构
[1] Med Technol & Practice Patterns Inst, Bethesda, MD 20814 USA
[2] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA
[3] Harvard Mit Div Hlth Sci & Technol, Boston, MA USA
[4] Johns Hopkins Univ, Sch Med, Baltimore, MD USA
基金
美国国家卫生研究院;
关键词
CAUSAL MODELING; MARGINAL STRUCTURAL MODEL; SYSTEMIC LUPUS ERYTHEMATOSUS; CORTICOSTEROID TREATMENT; LONGTERM PREDNISONE THERAPY; PERMANENT ORGAN DAMAGE; MARGINAL STRUCTURAL MODELS; DISEASE-ACTIVITY; INDEX; ERYTHEMATOSUS; COHORT; TIME; ZIDOVUDINE; MORTALITY; THERAPY;
D O I
10.3899/jrheum.080828
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective. To estimate the effect of corticosteroids (prednisone dose) on permanent organ damage among persons with systemic lupus erythematosus (SLE). Methods. We identified 525 patients with incident SLE in the Hopkins Lupus Cohort. At each visit, clinical activity indices, laboratory data, and treatment were recorded. The study population was followed from the month after the first visit until June 29, 2006, or attainment of irreversible organ damage, death, loss to followup, or receipt of pulse methylprednisolone therapy. We estimated the effect of cumulative average dose of prednisone on organ damage using a marginal structural model to adjust for time-dependent confounding by indication due to SLE disease activity. Results. Compared with non-prednisone use, the hazard ratio of organ damage for prednisone was 1.16 (95% CI 0.54. 2.50) for Cumulative average doses > 0-180 mg/month, 1.50 (95% CI 0.58, 3.88) for > 180-360 mg/month, 1.64 (95% CI 0.58, 4.69) for > 360-540 mg/month, and 2.51 (95% CI 0.87, 7.27) for > 540 mg/month. In contrast, standard Cox regression models estimated higher hazard ratios at all dose levels. Conclusion. Our results suggest that low doses of prednisone do not result in a substantially increased risk of irreversible organ damage. (First Release Feb 1 2009; J Rheumatol 2009;36:560-4; doi: 10.3899/jrheum.080828)
引用
收藏
页码:560 / 564
页数:5
相关论文
共 21 条
[1]   DERIVATION OF THE SLEDAI - A DISEASE-ACTIVITY INDEX FOR LUPUS PATIENTS [J].
BOMBARDIER, C ;
GLADMAN, DD ;
UROWITZ, MB ;
CARON, D ;
CHANG, CH .
ARTHRITIS AND RHEUMATISM, 1992, 35 (06) :630-640
[2]   Methotrexate and mortality in patients with rheumatoid arthritis:: a prospective study [J].
Choi, HK ;
Hernán, MA ;
Seeger, JD ;
Robins, JM ;
Wolfe, F .
LANCET, 2002, 359 (9313) :1173-1177
[3]   Effect of highly active antiretroviral therapy on time to acquired immunodeficiency syndrome or death using marginal structural models [J].
Cole, SR ;
Hernán, MA ;
Robins, JM ;
Anastos, K ;
Chmiel, J ;
Detels, R ;
Ervin, C ;
Feldman, J ;
Greenblatt, R ;
Kingsley, L ;
Lai, SH ;
Young, M ;
Cohen, M ;
Muñoz, A .
AMERICAN JOURNAL OF EPIDEMIOLOGY, 2003, 158 (07) :687-694
[4]   Use of a marginal structural model to determine the effect of aspirin on cardiovascular mortality in the physicians' health study [J].
Cook, NR ;
Cole, SR ;
Hennekens, CH .
AMERICAN JOURNAL OF EPIDEMIOLOGY, 2002, 155 (11) :1045-1053
[5]   The development and initial validation of the systemic lupus international collaborating clinics American College of Rheumatology Damage Index for Systemic Lupus Erythematosus [J].
Gladman, D ;
Ginzler, E ;
Goldsmith, C ;
Fortin, P ;
Liang, M ;
Urowitz, M ;
Bacon, P ;
Bombardieri, S ;
Hanly, J ;
Hay, E ;
Isenberg, D ;
Jones, J ;
Kalunian, K ;
Maddison, P ;
Nived, O ;
Petri, M ;
Richter, M ;
SanchezGuerrero, J ;
Snaith, M ;
Sturfelt, G ;
Symmons, D ;
Zoma, A .
ARTHRITIS AND RHEUMATISM, 1996, 39 (03) :363-369
[6]   The reliability of the systemic Lupus International Collaborating Clinics American College of Rheumatology Damage Index in patients with Systemic Lupus Erythematosus [J].
Gladman, DD ;
Urowitz, MB ;
Goldsmith, CH ;
Fortin, P ;
Ginzler, E ;
Gordon, C ;
Hanly, JG ;
Isenberg, DA ;
Kalunian, K ;
Nived, O ;
Petri, M ;
SanchezGuerrero, J ;
Snaith, M ;
Sturfelt, G .
ARTHRITIS AND RHEUMATISM, 1997, 40 (05) :809-813
[7]  
Gladman DD, 2003, J RHEUMATOL, V30, P1955
[8]   New therapies for systemic lupus erythematosus [J].
Goldblatt, F ;
Isenberg, DA .
CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2005, 140 (02) :205-212
[9]   Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men [J].
Hernán, MA ;
Brumback, B ;
Robins, JM .
EPIDEMIOLOGY, 2000, 11 (05) :561-570
[10]   A structural approach to selection bias [J].
Hernán, MA ;
Hernández-Díaz, S ;
Robins, JM .
EPIDEMIOLOGY, 2004, 15 (05) :615-625